Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice.

Authors:
Dr. Takeshi Yamamoto, PhD
Dr. Takeshi Yamamoto, PhD
Japan Tobacco Inc.
Senior Research Scientist
Enzymology
Yokohama | Japan
Ichizo Nishino, MD, PhD
Ichizo Nishino, MD, PhD
National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP)
Director, Department of Neuromuscular Research
Muscle disease
Kodaira, Tokyo | Japan

Brain 2014 Oct 24;137(Pt 10):2670-9. Epub 2014 Jul 24.

1 Department of Neuromuscular Research, National Institute of Neuroscience, National Centre of Neurology and Psychiatry (NCNP), Tokyo, Japan 4 Department of Clinical Development, Translational Medical Centre, NCNP, Tokyo, Japan

Patients with GNE myopathy, a progressive and debilitating disease caused by a genetic defect in sialic acid biosynthesis, rely on supportive care and eventually become wheelchair-bound. To elucidate whether GNE myopathy is treatable at a progressive stage of the disease, we examined the efficacy of sialic acid supplementation on symptomatic old GNE myopathy mice that have ongoing, active muscle degeneration. We examined the therapeutic effect of a less metabolized sialic acid compound (6'-sialyllactose) or free sialic acid (N-acetylneuraminic acid) by oral, continuous administration to 50-week-old GNE myopathy mice for 30 weeks. To evaluate effects on their motor performance in living mice, spontaneous locomotion activity on a running wheel was measured chronologically at 50, 65, 72 and 80 weeks of age. The size, force production, and pathology of isolated gastrocnemius muscle were analysed at the end point. Sialic acid level in skeletal muscle was also measured. Spontaneous locomotion activity was recovered in 6'-sialyllactose-treated mice, while NeuAc-treated mice slowed the disease progression. Treatment with 6'-sialyllactose led to marked restoration of hyposialylation in muscle and consequently to robust improvement in the muscle size, contractile parameters, and pathology as compared to NeuAc. This is due to the fact that 6'-sialyllactose is longer working as it is further metabolized to free sialic acid after initial absorption. 6'-sialyllactose ameliorated muscle atrophy and degeneration in symptomatic GNE myopathy mice. Our results provide evidence that GNE myopathy can be treated even at a progressive stage and 6'-sialyllactose has more remarkable advantage than free sialic acid, providing a conceptual proof for clinical use in patients.

Download full-text PDF

Source
http://brain.oxfordjournals.org/content/brain/early/2014/07/
Web Search
http://www.brain.oxfordjournals.org/cgi/doi/10.1093/brain/aw
Publisher Site
http://dx.doi.org/10.1093/brain/awu210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172045PMC
October 2014
61 Reads
15 Citations
9.200 Impact Factor

Publication Analysis

Top Keywords

gne myopathy
28
sialic acid
28
symptomatic gne
12
myopathy mice
12
free sialic
12
progressive stage
8
spontaneous locomotion
8
acid
8
locomotion activity
8
mice
7
gne
7
myopathy
7
sialic
7
muscle
6
6'-sialyllactose
5
activity running
4
initial absorption
4
running wheel
4
weeks age
4
size force
4

References

(Supplied by CrossRef)
A service of the U.S. National Institute of Health
ClinicalTrials.gov [Internet] et al.
Autophagy in lysosomal myopathies
Malicdan et al.
Brain Pathol 2012

Similar Publications